Gilead Sciences Acquires Arcellx for $7.8 Billion to Expand CAR T Cell Therapy Portfolio
February 21, 2026
Gilead Sciences entered into a definitive agreement to acquire Arcellx for $115 per share in cash plus a $5 per share contingent value right, implying an equity value of about $7.8 billion. The deal was completed on April 27, 2026, with Arcellx becoming a wholly owned subsidiary and full control of anito-cel and Arcellx’s D-Domain CAR technology platform.
- Buyers
- Gilead Sciences
- Targets
- Arcellx, Inc.
- Industry
- Healthcare Services
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.